CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Rein Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Rein Therapeutics Inc
12407 N. Mopac Expy., Suite 250 #390
Phone: (617) 995-0900p:617 995-0900 AUSTIN, TX  78758  United States Ticker: RNTXRNTX
Business Summary
Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Josef H.Von Rickenbach 69 10/21/2023 6/19/2019
President, Chief Executive Officer, Director BrianWindsor 58 3/11/2024 10/31/2023
Interim Chief Financial Officer Timothy M.Cunningham 62 5/16/2024 5/16/2024
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Lung Therapeutics, Inc. 3801 S Capital of Texas Hwy Austin Texas United States

Business Names
Business Name
ALRN
Lung Therapeutics Australia Pty Ltd
Lung Therapeutics Limited
Lung Therapeutics, Inc.
Lung Therapeutics, LLC
RNTX

General Information
Number of Employees: 15 (As of 12/31/2023)
Outstanding Shares: 21,665,941 (As of 11/12/2024)
Shareholders: 467
Stock Exchange: NASD
Federal Tax Id: 134196017
Fax Number: (617) 995-2410


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025